Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop
Top Cited Papers
- 15 November 2012
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 160 (2), 171-176
- https://doi.org/10.1111/bjh.12102
Abstract
This report represents a further update of the consensus panel criteria for the assessment of clinical response in patients with Waldenström macroglobulinaemia (WM). These criteria have been updated in light of further data demonstrating an improvement in categorical responses with new drug regimens as well as acknowledgement of the fact that such responses are predictive of overall outcome. A number of key changes are proposed but challenges do however remain and these include the variability in kinetics of immunoglobulin M (IgM) reduction with different treatment modalities and the apparent discrepancy between IgM and bone marrow/tissue response noted with some regimens. Planned sequential bone marrow assessments are encouraged in clinical trials.Keywords
This publication has 31 references indexed in Scilit:
- Long-Term Biological Variation of Serum Protein Electrophoresis M-Spike, Urine M-Spike, and Monoclonal Serum Free Light Chain Quantification: Implications for Monitoring Monoclonal GammopathiesClinical Chemistry, 2011
- The role of 18F‐FDG PET/CT imaging in Waldenstrom macroglobulinemiaAmerican Journal of Hematology, 2011
- Residual Monotypic Plasma Cells in Patients With Waldenström Macroglobulinemia After TherapyAmerican Journal of Clinical Pathology, 2011
- Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Rituximab and Subcutaneous 2-Chloro-2′-Deoxyadenosine Combination Treatment for Patients With Waldenström Macroglobulinemia: Clinical and Biologic Results of a Phase II Multicenter StudyJournal of Clinical Oncology, 2010
- Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow‐up of the Eastern Cooperative Oncology Group E3A98 trialBritish Journal of Haematology, 2009
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Serum-free light chain elevation is associated with a shorter time to treatment in Waldenstrom's macroglobulinemiaHaematologica, 2008
- Bortezomib Is Active in Patients With Untreated or Relapsed Waldenström's Macroglobulinemia: A Phase II Study of the National Cancer Institute of Canada Clinical Trials GroupJournal of Clinical Oncology, 2007
- Update on Recommendations for Assessing Response from the Third International Workshop on Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2006